Table 2

Baseline characteristics of patients sustaining remission or relapsing

Total populationACPA-positive patients
CharacteristicsSustained remission
(N=67)
Relapse
(N=34)
p ValuesSustained remission
(N=36)
Relapse
(N=24)
p Values
Age, years59.0 (17)55.0 (21)0.84950.0 (16)52.0 (17)0.608
Female gender, % (N)55.2 (37)73.5 (25)0.08750.0 (18)83.3 (20)0.013
Disease duration, years5.0 (6)6.0 (7)0.2785.0 (6)6.0 (7)0.868
Remission duration, months11.5 (12)12.0 (12)0.88411.0 (20)13.0 (18)0.925
DAS28, Units1.82 (1.1)2.08 (0.6)0.0711.68 (1.1)2.06 (0.7)0.131
ACR/EULAR remission, % (N)77.6 (52)76.5 (26)0.80369.4 (25)83.3 (20)0.361
Tender joint count 28, N0.0 (0)0.0 (0)0.5860.0 (0)0.0 (0)0.496
Swollen joint count 28, N0.0 (0)0.0 (0)0.3620.0 (0)0.0 (0)0.057
VAS patient global, mm0.0 (6)0.0 (6)0.5830.5 (9)0.0 (5)0.436
ESR, mm11.0 (13)15.0 (13)0.0809.0 (11)14.0 (14)0.157
CRP, mg/dL0.23 (0.3)0.30 (0.4)0.1700.21 (0.3)0.30 (0.3)0.386
HAQ, Units0.0 (0.3)0.0 (0.2)0.8470.0 (0.1)0.0 (0.1)0.714
Positive RF, % (N)59.7 (40)70.6 (24)0.38391.7 (33)83.3 (20)0.422
Positive ACPA, % (N)53.7 (36)70.6 (24)0.126
Methotrexate use, % (N)85.1 (57)76.5 (26)0.40988.9 (32)75.0 (18)0.178
Other DMARD* use, % (N)10.4 (7)8.8 (3)1.0008.3 (3)8.3 (2)1.000
Biological DMARD† use, % (N)37.3 (25)47.1 (16)0.39547.2 (17)45.8 (11)1.000
  • Significant values are shown in bold typeface.

  • *Leflunomide, sulfasalazine, hydroxychloroquine.

  • †Tumour necrosis factor inhibitors and tocilizumab; data show medians and IQRs.

  • ACPA, anti-citrullinated protein antibodies; ACR, American College of Rheumatology; CRP, C-reactive protein; DAS28, disease activity score 28 (based on ESR); DMARDs, disease-modifying antirheumatic drugs; ESR, erythrocyte sedimentation rate; EULAR, European League Against Rheumatism; HAQ, health assessment questionnaire; RF, rheumatoid factor; VAS, visual analogue scale.